Winslow Evans & Crocker’s abrdn Life Sciences Investors HQL Stock Holding History

Winslow Evans & Crocker’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$269K	Buy	13,610 +573	+4%	+$10.6K	0.05%	290
2020 Q3	$229K	Buy	13,037 +238	+2%	+$4.26K	0.06%	253
2020 Q2	$230K	Sell	12,799 -1	-0%	-$17	0.06%	249
2020 Q1	$192K	Buy	12,800 +390	+3%	+$6.39K	0.06%	248
2019 Q4	$218K	Buy	12,410 +510	+4%	+$8.37K	0.06%	279
2019 Q3	$180K	Buy	+11,900	New	+$191K	0.05%	294

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Winslow Evans & Crocker's HQL Position: Q4 2020 in Review

Winslow Evans & Crocker increased its abrdn Life Sciences Investors (HQL) stake by 4.4% in Q4 2020, buying an estimated $10.6K and bringing the position to 13,610 shares worth $269K. The position accounts for 0.05% of the portfolio, ranked #290.

Winslow Evans & Crocker first reported a position in HQL in Q3 2019 and has held it in 6 quarters since. 66 funds tracked by Wall St. Rank hold HQL as of Q4 2020.

Winslow Evans & Crocker held 13,610 shares of abrdn Life Sciences Investors worth $269K as of Q4 2020.
Winslow Evans & Crocker bought 573 abrdn Life Sciences Investors shares in Q4 2020, an estimated $10.6K.
abrdn Life Sciences Investors made up 0.05% of Winslow Evans & Crocker's portfolio in Q4 2020, its #290 holding.
Winslow Evans & Crocker first reported a position in abrdn Life Sciences Investors in Q3 2019 and has held it in 6 quarters since.
66 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.